Leili Fatehi, Susan M. Wolf, Jeffrey McCullough, Ralph Hall, Frances Lawrenz, Jeffrey P. Kahn, Cortney Jones, Stephen A. Campbell, Rebecca S. Dresser, Arthur G. Erdman, Christy L. Haynes, Robert A. Hoerr, Linda F. Hogle, Moira A. Keane, George Khushf, Nancy M. P. King, Efrosini Kokkoli, Gary Marchant, Andrew D. Maynard, Martin Philbert, Gurumurthy Ramachandran, Ronald A. Siegel & Samuel Wickline
Journal of Law, Medicine and Ethics 40 (4):716-750 (2012)
Abstract |
Nanomedicine is yielding new and improved treatments and diagnostics for a range of diseases and disorders. Nanomedicine applications incorporate materials and components with nanoscale dimensions where novel physiochemical properties emerge as a result of size-dependent phenomena and high surface-to-mass ratio. Nanotherapeutics and in vivo nanodiagnostics are a subset of nanomedicine products that enter the human body. These include drugs, biological products, implantable medical devices, and combination products that are designed to function in the body in ways unachievable at larger scales. Nanotherapeutics and in vivo nanodiagnostics incorporate materials that are engineered at the nanoscale to express novel properties that are medicinally useful. These nanomedicine applications can also contain nanomaterials that are biologically active, producing interactions that depend on biological triggers. Examples include nanoscale formulations of insoluble drugs to improve bioavailability and pharmacokinetics, drugs encapsulated in hollow nanoparticles with the ability to target and cross cellular and tissue membranes and to release their payload at a specific time or location, imaging agents that demonstrate novel optical properties to aid in locating micrometastases, and antimicrobial and drug-eluting components or coatings of implantable medical devices such as stents.
|
Keywords | No keywords specified (fix it) |
Categories | (categorize this paper) |
DOI | 10.1111/j.1748-720x.2012.00703.x |
Options |
![]() ![]() ![]() ![]() |
Download options
References found in this work BETA
Therapeutic Misconception in Clinical Research: Frequency and Risk Factors.Paul S. Appelbaum, Charles W. Lidz & Thomas Grisso - 2004 - IRB: Ethics & Human Research 26 (2):1.
Empirical Issues in Informed Consent for Research.James Flory, David Wendler & Ezekiel Emanuel - 2008 - In Ezekiel J. Emanuel (ed.), The Oxford Textbook of Clinical Research Ethics. Oxford University Press. pp. 645--60.
Ethics and Nanopharmacy: Value Sensitive Design of New Drugs. [REVIEW]Job Timmermans, Yinghuan Zhao & Jeroen van den Hoven - 2011 - NanoEthics 5 (3):269-283.
Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty.Jonathan Kimmelman & Alex John London - unknown
View all 16 references / Add more references
Citations of this work BETA
Rethinking Risk Assessment for Emerging Technology First-in-Human Trials.Anna Genske & Sabrina Engel-Glatter - 2016 - Medicine, Health Care and Philosophy 19 (1):125-139.
Nanomedicine First-in-Human Research: Challenges for Informed Consent.Nancy M. P. King - 2012 - Journal of Law, Medicine and Ethics 40 (4):823-830.
Concepts of Risk in Nanomedicine Research.Linda F. Hogle - 2012 - Journal of Law, Medicine and Ethics 40 (4):809-822.
Concepts of Risk in Nanomedicine Research.Linda F. Hogle - 2012 - Journal of Law, Medicine and Ethics 40 (4):809-822.
The Clinical Research of Nanomedicine: A New Ethical Challenge?Urban Wiesing & Jens Clausen - 2014 - NanoEthics 8 (1):19-28.
View all 8 citations / Add more citations
Similar books and articles
Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations.Susan M. Wolf, Frances P. Lawrenz, Charles A. Nelson, Jeffrey P. Kahn, Mildred K. Cho, Ellen Wright Clayton, Joel G. Fletcher, Michael K. Georgieff, Dale Hammerschmidt, Kathy Hudson, Judy Illes, Vivek Kapur, Moira A. Keane, Barbara A. Koenig, Bonnie S. LeRoy, Elizabeth G. McFarland, Jordan Paradise, Lisa S. Parker, Sharon F. Terry, Brian Van Ness & Benjamin S. Wilfond - 2008 - Journal of Law, Medicine and Ethics 36 (2):219-248.
Moving Beyond Compliance: Measuring Ethical Quality to Enhance the Oversight of Human Subjects Research.Holly Taylor - 2007 - IRB: Ethics & Human Research 29 (5).
A Policy in Flux: New York State's Evolving Approach to Human Subjects Research Involving Individuals Who Lack Consent Capacity.Valerie Gutmann Koch - 2014 - Journal of Law, Medicine and Ethics 42 (3):383-388.
Gene Therapy Oversight: Lessons for Nanobiotechnology.Susan M. Wolf, Rishi Gupta & Peter Kohlhepp - 2009 - Journal of Law, Medicine and Ethics 37 (4):659-684.
Revolution or Reform in Human Subjects Research Oversight.Steven Joffe - 2012 - Journal of Law, Medicine and Ethics 40 (4):922-929.
Commentary: Who's Afraid of the RAC? Lessons From the Oversight of Controversial Science.Jeffrey P. Kahn - 2009 - Journal of Law, Medicine and Ethics 37 (4):685-687.
Post-Approval Monitoring and Oversight of U.S.-Initiated Human Subjects Research in Resource-Constrained Countries.Brandon Brown, Janni Kinsler, Morenike O. Folayan, Karen Allen & Carlos F. Cáceres - 2014 - Journal of Bioethical Inquiry 11 (2):119-123.
Ethical International Research on Human Subjects Research in the Absence of Local Institutional Review Boards.S. B. Bhat - 2006 - Journal of Medical Ethics 32 (9):535-536.
Developing U.S. Oversight Strategies for Nanobiotechnology: Learning From Past Oversight Experiences.Jordan Paradise, Susan M. Wolf, Jennifer Kuzma, Aliya Kuzhabekova, Alison W. Tisdale, Efrosini Kokkoli & Gurumurthy Ramachandran - 2009 - Journal of Law, Medicine and Ethics 37 (4):688-705.
Problems with Minimal-Risk Research Oversight: A Threat to Academic Freedom?Lisa M. Rasmussen - 2009 - IRB: Ethics & Human Research 31 (3):11.
Remedies for Human Subjects of Cold War Research: Recommendations of the Advisory Committee.Anna Mastroianni & Jeffrey Kahn - 1996 - Journal of Law, Medicine and Ethics 24 (2):118-126.
Remedies for Human Subjects of Cold War Research: Recommendations of the Advisory Committee.Anna Mastroianni & Jeffrey Kahn - 1996 - Journal of Law, Medicine and Ethics 24 (2):118-126.
New Rules for Research with Human Participants?Jessica Berg & Nicole Deming - 2011 - Hastings Center Report 41 (6):10-11.
Improving Protection for Human Research Subjects: Better Oversight, Not Just More Oversight.Neil W. Schluger - 2008 - American Journal of Bioethics 8 (11):13 – 15.
An Empirical Examination of the Current State of Publically Available Nanotechnology Guidance Materials.Laura Fleege & Frances Lawrenz - 2012 - Journal of Law, Medicine and Ethics 40 (4):751-762.
Analytics
Added to PP index
2013-03-01
Total views
76 ( #150,137 of 2,497,803 )
Recent downloads (6 months)
3 ( #212,593 of 2,497,803 )
2013-03-01
Total views
76 ( #150,137 of 2,497,803 )
Recent downloads (6 months)
3 ( #212,593 of 2,497,803 )
How can I increase my downloads?
Downloads